Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.72
Bid: 3.58
Ask: 3.88
Change: 0.00 (0.00%)
Spread: 0.30 (8.38%)
Open: 3.72
High: 0.00
Low: 0.00
Prev. Close: 3.72
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New US PREtec Patents Issued

6 Oct 2020 07:00

RNS Number : 0115B
Plant Health Care PLC
06 October 2020
 

Reach

6 October 2020

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

Four US patents issue for PREtec peptide products

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce the granting of four new US patents for its novel PREtec peptide technology.

 Highlights

 

- Plant Health Care has filed more than 50 patent applications worldwide for its PREtec peptide technology since 2012

- Four additional patents have now been granted by the US Patent and Trademark Office (USPTO)

- The patents provide protection for a wide range of PREtec peptides for a variety of agricultural uses

- Additional patents are expected to be granted prior to the end of the year

 

PREtec is a novel, environmentally friendly approach to growing crops more sustainably. PREtec peptides can be thought of as 'vaccines for plants' - they stimulate the plants' natural defence systems and result in improved crop yield and quality.

 

Three of the four patents share the same title, "Elicitor Peptides Having Disrupted Hypersensitive Response Box And Use Thereof," and issued January 7, 2020, as U.S. patent No. 10,524,472 and U.S. patent No. 10,524,473, and on August 18, 2020, as U.S. patent No. 10,743,538. The fourth patent, titled "Hypersensitive Response Elicitor-Derived Peptides And Use Thereof," issued on October 6, 2020, as U.S. patent No. 10,793,608.

 

These patents, in addition to US patent No. 10,470,461 which issued in 2019, claim a large number of unique plant response elicitor peptides that when applied activate a plant to defend itself, thereby 'vaccinating' plants against a variety of environmental stresses such as disease and drought, enhancing root and shoot growth, and promoting yield and crop quality at harvest.

 

For example, in almond trials conducted in California during the 2018 and 2019 growing seasons, the application of a PREtec peptide resulted in increasing the almond yield by more than fifteen percent compared to the standard practices. At recent almond prices, this additional yield would have been worth more than $800/acre to the grower. Multiple foreign patents corresponding to these US PREtec patents are expected to issue during the next 12-24 months.

 

As previously announced, the Company is now poised to launch the first products from a broad pipeline of PREtec peptides, targeting markets which have a value of greater than $5 billion. The Company has developed a global scientific lead in the use of plant response elicitor peptides for agriculture, with a number of patents now granted in the US.

 

Chris Richards, CEO of Plant Health Care, said, "Receiving these new patents is another step towards securing Plant Health Care's position as the leading innovator of peptides for agriculture. The Company has developed a global scientific lead in the use of plant response elicitor peptides for agriculture, with a number of patents now granted in the US. These patents cover an immense number of future product candidates which we are continuing to develop to solve a variety of urgent problems faced by farmers. We are preparing to launch this novel technology directly to markets in USA, Brazil and other countries, once regulatory permits are in place. The Company expects to begin the commercialization of products based on PREtec intellectual property in 2022."  

 

For further information, please contact:

Plant Health Care plc

Chris Richards, CEO, Tel: +1 919 926 1600

 

Arden Partners plc - Nomad & Broker

John Llewellyn-Lloyd / Dan Gee-Summons Tel: +44 (0) 20 7614 5900

 

Company website: www.planthealthcare.com

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAELLFBBBLZFBQ
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.